StockNews.com initiated coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Free Report) (TSE:AEZ) in a research note released on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
Shares of NASDAQ AEZS opened at $6.84 on Thursday. Aeterna Zentaris has a 1 year low of $3.96 and a 1 year high of $12.80. The stock has a market cap of $12.24 million, a P/E ratio of -0.46 and a beta of 1.55. The firm has a 50-day moving average of $7.00 and a 200 day moving average of $7.52.
Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) last issued its quarterly earnings results on Tuesday, May 14th. The biopharmaceutical company reported ($4.74) earnings per share (EPS) for the quarter. Aeterna Zentaris had a negative net margin of 760.32% and a negative return on equity of 83.45%.
About Aeterna Zentaris
Aeterna Zentaris Inc, a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests in Canada, Switzerland, Ireland, Denmark, Germany, the United States, and internationally. Its lead product is Macrilen (macimorelin), an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of patients with adult growth hormone deficiency and childhood-onset growth hormone deficiency, as well as endocrinology and oncology indications; AEZS-150, a delayed clearance parathyroid hormone fusion polypeptide that is in preclinical trial for the treatment of chronic hypoparathyroidism; and AEZS-130 that is in preclinical trial for the treatment of amyotrophic lateral sclerosis.
Featured Stories
- Five stocks we like better than Aeterna Zentaris
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Sales Breakout Sends This Semiconductor Stock to Record High
- Earnings Per Share Calculator: How to Calculate EPS
- Surprise Buying Opportunity on This Dividend Aristocrat
- Transportation Stocks Investing
- New Theme Park Powerhouse: Merger Creates Industry-Leading Stock
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.